Corvus Pharmaceuticals Inc
Suletud
11.12 -4.71
Ülevaade
Aktsiahinna muutus
24h
Min
11.03
Max
11.24
Sissetulek | -1.4M -14M |
|---|---|
Aktsiakasum | -0.15 |
Töötajad | 37 |
EBITDA | -2.7M -15M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +184.17% upside |
Järgmine tulemuste avaldamine | 6. aug 2026 |
|---|
Turukapital | -331M 1B |
|---|---|
Eelmine avamishind | 15.83 |
Eelmine sulgemishind | 11.12 |
Corvus Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Corvus Pharmaceuticals Inc Prognoos
Hinnasiht
By TipRanks
184.17% tõus
12 kuu keskmine prognoos
Keskmine 31.6 USD 184.17%
Kõrge 40 USD
Madal 27 USD
Põhineb 5 Wall Streeti analüütiku instrumendi Corvus Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
